Kairos Pharma Ltd. (KAPA)
0.92
-0.05 (-5.15%)
At close: Mar 28, 2025, 3:59 PM
1.00
8.53%
After-hours: Mar 28, 2025, 06:45 PM EDT
Company Description
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients.
Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016.
The company was incorporated in 2013 and is based in Los Angeles, California.
Kairos Pharma Ltd.
| Country | United States |
| IPO Date | Sep 16, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Dr. John S. Yu M.D., Ph.D. |
Contact Details
Address: 2355 Westwood Blvd. Los Angeles, California United States | |
| Website | https://kairospharma.com |
Stock Details
| Ticker Symbol | KAPA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001962011 |
| CUSIP Number | n/a |
| ISIN Number | US48301N1046 |
| Employer ID | 46-2993314 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John S. Yu M.D., Ph.D. | Chief Executive Officer, Chairman & Secretary |
| Douglas W. Samuelson CPA | Chief Financial Officer |
| Dr. Neil A. Bhowmick Ph.D. | Chief Scientific Officer |
| Dr. Ramachandran Murali Ph.D. | Vice President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 24, 2025 | 4 | Filing |
| Feb 24, 2025 | 4 | Filing |
| Feb 10, 2025 | DEF 14C | Filing |
| Feb 06, 2025 | 8-K | Current Report |
| Feb 05, 2025 | 424B3 | Filing |
| Jan 29, 2025 | PRE 14C | Filing |
| Jan 29, 2025 | S-1 | Filing |
| Jan 28, 2025 | D | Filing |